Abstract
Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers. Of 302 children with hemangiomas seen at the University of North Carolina from 2008 through 2010, 15.6% were treated with oral propranolol alone, 5.6% with topical timolol (a propranolol derivative) alone, and 2.3% with both. The use of these agents increased over time from 7% of patients seen in 2008 to 54% of patients first seen in 2010. Starting doses of propranolol ranged from 0.25 to 1 mg/kg/d, with target doses of 1 to 4 mg/kg/d. Serious side effects, noted in 6/54 (10.9%) patients, included somnolence, bradycardia, hypotension, hypoglycemia, and mottling of extremities.The authors confirm the variation in use of propranolol for vascular lesions and extend experience with timolol. They suggest daily home monitoring of patients for the first 2 weeks of initiating or increasing doses. Frequent feeding of infants and young children on this drug is recommended.
| Original language | English |
|---|---|
| Pages (from-to) | 757-763 |
| Number of pages | 7 |
| Journal | Clinical Pediatrics |
| Volume | 50 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2011 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pediatrics, Perinatology, and Child Health
Cite this
β-blockers for infantile hemangiomas : A single-institution experience. / Blatt, Julie; Morrell, Dean S.; Buck, Scott; Zdanski, Carlton; Gold, Stuart; Stavas, Joseph; Powell, Cynthia; Burkhart, Craig N.
In: Clinical Pediatrics, Vol. 50, No. 8, 08.2011, p. 757-763.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - β-blockers for infantile hemangiomas
T2 - A single-institution experience
AU - Blatt, Julie
AU - Morrell, Dean S.
AU - Buck, Scott
AU - Zdanski, Carlton
AU - Gold, Stuart
AU - Stavas, Joseph
AU - Powell, Cynthia
AU - Burkhart, Craig N.
PY - 2011/8
Y1 - 2011/8
N2 - Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers. Of 302 children with hemangiomas seen at the University of North Carolina from 2008 through 2010, 15.6% were treated with oral propranolol alone, 5.6% with topical timolol (a propranolol derivative) alone, and 2.3% with both. The use of these agents increased over time from 7% of patients seen in 2008 to 54% of patients first seen in 2010. Starting doses of propranolol ranged from 0.25 to 1 mg/kg/d, with target doses of 1 to 4 mg/kg/d. Serious side effects, noted in 6/54 (10.9%) patients, included somnolence, bradycardia, hypotension, hypoglycemia, and mottling of extremities.The authors confirm the variation in use of propranolol for vascular lesions and extend experience with timolol. They suggest daily home monitoring of patients for the first 2 weeks of initiating or increasing doses. Frequent feeding of infants and young children on this drug is recommended.
AB - Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers. Of 302 children with hemangiomas seen at the University of North Carolina from 2008 through 2010, 15.6% were treated with oral propranolol alone, 5.6% with topical timolol (a propranolol derivative) alone, and 2.3% with both. The use of these agents increased over time from 7% of patients seen in 2008 to 54% of patients first seen in 2010. Starting doses of propranolol ranged from 0.25 to 1 mg/kg/d, with target doses of 1 to 4 mg/kg/d. Serious side effects, noted in 6/54 (10.9%) patients, included somnolence, bradycardia, hypotension, hypoglycemia, and mottling of extremities.The authors confirm the variation in use of propranolol for vascular lesions and extend experience with timolol. They suggest daily home monitoring of patients for the first 2 weeks of initiating or increasing doses. Frequent feeding of infants and young children on this drug is recommended.
UR - http://www.scopus.com/inward/record.url?scp=80052518387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052518387&partnerID=8YFLogxK
U2 - 10.1177/0009922811405517
DO - 10.1177/0009922811405517
M3 - Article
VL - 50
SP - 757
EP - 763
JO - Clinical Pediatrics
JF - Clinical Pediatrics
SN - 0009-9228
IS - 8
ER -